Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2020-04-22 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
2020年第三次临时股东大会的律师见证法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2020 third extraordinary general meeting (临时股东大会) of shareholders of 瑞康医药集团股份有限公司. It details the legal verification of the meeting's convening, attendance, agenda, voting procedures, and results. The document does not contain financial statements or financial performance data but focuses on the legality and procedural correctness of the shareholder meeting and its resolutions. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, not an annual report, earnings release, or proxy solicitation. Therefore, the most appropriate classification is Legal Proceedings Report (LTR). The document length is 4276 characters, which is sufficient for a full legal opinion letter, not a brief announcement or certification.
2020-04-22 Chinese
2020年第三次临时股东大会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2020 third extraordinary general meeting of shareholders of Ruikang Pharmaceutical Group Co., Ltd. It includes details about the meeting notice, attendance, voting results, and legal opinion on the meeting's validity. The document does not contain full financial statements or detailed financial performance data, but rather the official voting results and meeting decisions. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1624 characters) and it is not a report publication announcement or a regulatory filing. Therefore, the correct classification is DVA with high confidence.
2020-04-22 Chinese
2018年面向合格投资者公开发行公司债券（第一期）2020年付息公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the interest payment for a corporate bond issued by 瑞康医药集团股份有限公司 in 2018. It details the bond's basic information, interest rate, payment dates, tax implications, and contact information. The document is focused on the payment of interest for the bond in 2020 and does not contain financial statements or comprehensive financial performance data. It is not a full financial report but an update on a financing activity related to bond interest payment. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is about 4997 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report.
2020-04-16 Chinese
关于“18瑞康01”投资者回售结果的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of investor put-back (回售) of a specific bond "18瑞康01" issued by 瑞康医药集团股份有限公司. It details the number of bonds put back, the amount, interest payment, and the payment date. It does not contain financial statements or detailed financial analysis but rather reports on the outcome of a bond investor action and payment arrangements. This fits the category of a Capital/Financing Update (CAP), as it relates to bond financing and investor redemption results.
2020-04-16 Chinese
关于为全资及控股子公司提供担保的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 瑞康医药集团股份有限公司 regarding providing guarantees for its wholly-owned and controlled subsidiaries. It details the guarantee amounts, the relationship between guarantor and guaranteed entities, financial data of the subsidiaries, and opinions from the board, supervisory committee, and independent directors. The document is dated April 7, 2020, and includes resolutions from board and supervisory meetings. It is not a full financial report, audit report, or earnings release, but rather a regulatory announcement about guarantees provided by the company. This fits best under Regulatory Filings (RNS) as it is a compliance disclosure about guarantees and related financial risk, not a financial report or capital update.
2020-04-06 Chinese
关于变更会计政策的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 瑞康医药集团股份有限公司 regarding changes in accounting policies. It details the reasons for the changes, references specific accounting standards and regulations issued by the Ministry of Finance, and explains the impact of these changes on the company's financial statements. It also includes the board of directors' approval and independent directors' opinions on the changes. The document is not a full financial report but rather a formal announcement about accounting policy changes, which is typically classified under Regulatory Filings (RNS) as it does not contain comprehensive financial statements or detailed financial analysis. The document length is 4189 characters, which is relatively short and consistent with an announcement rather than a full report.
2020-04-06 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.